Adam Logal
Director of Finance/CFO at OPKO HEALTH, INC.
Net worth: 218 580 $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Steven Rubin | M | 63 |
OPKO Biologics Ltd.
 OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel.
eXegenics, Inc.
| 17 years |
| Phillip Frost | M | 87 |
eXegenics, Inc.
| 17 years |
| Jane Hsaio | M | 77 |
eXegenics, Inc.
| 17 years |
| Nell Beattie | F | 36 | 9 years | |
| Athena Kartsaklis | F | 59 | 7 years | |
| John Paganelli | M | 89 |
eXegenics, Inc.
| 21 years |
| Jeff Baxter | M | 62 | 8 years | |
| Allen Craig | M | - | 6 years | |
| Lin-Tsing Yu | M | 80 | 15 years | |
| Roger Medel | M | 77 | 4 years | |
| James Callaway | M | 68 | 7 years | |
| Richard Pfenniger | M | 68 | 16 years | |
| Grigory Borisenko | M | 55 | 5 years | |
| Gary Nabel | M | 70 | 2 years | |
| Michel de Wilde | M | 74 | 8 years | |
| Alexey Vinogradov | M | 54 | 5 years | |
| Firdaus Jal Dastoor | M | 72 | 10 years | |
| Roger Kornberg | M | 77 | 8 years | |
| James Parslow | M | 59 | 7 years | |
| Dmitriy Genkin | M | 56 | 5 years | |
| James Weisberger | M | 68 | 21 years | |
| Nicole Anderson | F | - | 7 years | |
| Elias Zerhouni | M | 72 | 2 years | |
| Prem Lachman | M | 64 | 3 years | |
| Richard Krasno | M | 82 | 7 years | |
| Jane Pine Wood | F | 62 | 8 years | |
| Oren Hershkovitz | M | 47 |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | 8 years |
| Victoria Laughman | F | - | - | |
| Laura Moschcovich | M | - |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | 4 years |
| Steve Schaeffer | M | 73 |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | 15 years |
| Elizabeth Nabel | M | 72 | 2 years | |
| Stephen A. Strugnell | M | - | 10 years | |
| David Anderson | M | 54 | 8 years | |
| Avi Mazaltov | M | 62 | 7 years | |
| Francisco Diaz-Mitoma | M | 69 | 8 years | |
| Moshe Mizrahy | M | 71 | - | |
| Jane Pine Wood | F | - | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Michael Scott Maguire | M | 61 | 3 years | |
| Marc Grodman | M | 72 | 35 years | |
| Jon Cohen | M | 70 | 3 years | |
| Curtis Lockshin | M | 64 | 13 years | |
| Jeffrey Eisenberg | M | 58 | 8 years | |
| Raafat E. F. Fahim | M | 70 |
Nabi Biopharmaceuticals
 Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | 9 years |
| Robert A. Baron | M | 84 |
eXegenics, Inc.
| 14 years |
| Warren W. Erdmann | M | - | 22 years | |
| Richard Alan Lerner | M | 85 |
eXegenics, Inc.
| 14 years |
| Subbarao Uppaluri | M | 75 |
eXegenics, Inc.
| 5 years |
| Sam Singer | M | 80 | 28 years | |
| Jordan I. Siegel | M | 58 |
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | 2 years |
| Anthony Japour | M | 64 | - | |
| Scott Requadt | M | 56 | 3 years | |
| Dave A. Eichler | M | - |
eXegenics, Inc.
| - |
| Peter B. Davis | M | 77 |
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | 6 years |
| Michael Reich | M | 81 |
eXegenics, Inc.
| 2 years |
| Kate Inman | F | - | 6 years | |
| Paul Kessler | M | 69 |
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | 7 years |
| Dmitry Yuryevich Kolosov | M | 44 | - | |
| Christopher McNulty | M | 47 | 5 years | |
| Robert S. Fishel | M | 62 | 4 years | |
| Alexis Borisy | M | 52 | 2 years | |
| Samuel Reich | M | 49 |
eXegenics, Inc.
| 1 years |
| Jason Aryeh | M | 56 |
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | 6 years |
| Howard Dubinett | M | 72 | 34 years | |
| Joseph Benincasa | M | 74 | 10 years | |
| Pascal J. Goldschmidt | M | - | 4 years | |
| Timothy Patrick Lynch | M | 54 |
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | 5 years |
| Harry Elias | M | 93 | 11 years | |
| John Roglieri | M | 84 | 20 years | |
| David J. Gury | M | 85 |
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | 20 years |
| Ben Bronstein | M | 74 | 1 years | |
| Mark L. Smith | M | 72 |
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | 7 years |
| Rulfo Hernandez | M | 45 | 7 years | |
| Ilan Kaufthal | M | 76 | - | |
| E. Scott Toner | M | - | 1 years | |
| Scott Moomaw | M | 54 | 2 years | |
| Jay Newmark | M | - | 4 years | |
| Geoff Monk | M | - | - | |
| Thomas Beier | M | 78 | - | |
| Igor Gitelman | M | 48 | 11 years | |
| Thomas Nusbickel | M | 67 | 2 years | |
| Daniel Haines | M | - | 1 years | |
| Gregory Henderson | M | - | - | |
| Patricia Sandler | F | 55 | - | |
| Jimmy Wang | M | - | 1 years | |
| Gili Hart | M | 49 |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | 13 years |
| Sam Chawla | M | 49 | 4 years | |
| Christine V. Sapan | M | 76 |
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | - |
| Roman Sergeevich Knyazev | M | 44 | 5 years | |
| David Okrongly | M | - | - | |
| George W. Ebright | M | 85 |
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | - |
| Ran Nussbaum | M | 51 | 1 years | |
| S. James Freedman | M | 57 | - | |
| Gordon F. Martin | M | - |
eXegenics, Inc.
| - |
| Melvin D. Rubin | M | - | - | |
| Daniel E. Greenleaf | M | 59 |
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | 1 years |
| Les Funtleyder | M | 54 | 2 years | |
| Melvin L. Rubin | M | - |
eXegenics, Inc.
| - |
| Dale Pfost | M | - |
eXegenics, Inc.
| - |
| Ronald Trust | M | - | - | |
| Juan F. Rodriguez | M | 56 | 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 96 | 96.00% |
| Israel | 5 | 5.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Adam Logal
- Personal Network
